`
`
`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`APPLICATION NUMBER:
`
`210595Orig1s000
`
`MULTI-DISCIPLINE REVIEW
`Summary Review
`Office Director
`Cross Discipline Team Leader Review
`Clinical Review
`Non-Clinical Review
`Statistical Review
`Clinical Pharmacology Review
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`
`NDA/BLA Multi‐Disciplinary Review and Evaluation
`
`Application Type NDA
`Application Number(s) 210595
`Priority or Standard Standard
`Submit Date(s) May 31, 2018
`Received Date(s) May 31, 2018
`PDUFA Goal Date March 31, 2019
`Division/Office Division of Pulmonary, Allergy, and Rheumatology Products
`Review Completion Date March 29, 2019
`Established/Proper Name Aclidinium bromide/formoterol fumarate inhalation powder
`(Proposed) Trade Name Duaklir Pressair
`Pharmacologic Class Long‐acting muscarinic/Long‐acting B2‐agonist
`Code name
`
`Applicant AstraZenecaPharmaceuticals LP
`Doseage form
`Inhalation powder
`Applicant proposed Dosing
`One inhalation (400 µg aclidinium bromide/ 12 µg formoterol
`Regimen
`fumarate) twice daily
`Applicant Proposed
`
`‐
` maintenance treatment of
`Indication(s)/Population(s)
`patients with chronic obstructive pulmonary disease (COPD),
`
`
`
`
`
`Approval
`
`
`Recommendation on
`Regulatory Action
`Recommended
`Indication(s)/Population(s)
`(if applicable)
`Recommended Dosing
`Regimen
`
`
`
`
`
` maintenance treatment of patients with COPD
`
`One inhalation (400 µg aclidinium bromide/ 12 µg formoterol
`fumarate) twice daily
`
`
`
`Version date: September 12, 2018
`
`
`
`1
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Table of Contents
`NDA/BLA Multi‐Disciplinary Review and Evaluation ...................................................................... 1
`Table of Tables ................................................................................................................................ 5
`Table of Figures ............................................................................................................................... 7
`Reviewers of Multi‐Disciplinary Review and Evaluation ................................................................ 9
`Glossary ......................................................................................................................................... 13
`1. Executive Summary ............................................................................................................... 15
`1.1. Product Introduction ...................................................................................................... 15
`1.2. Conclusions on the Substantial Evidence of Effectiveness ............................................ 15
`1.3. Benefit‐Risk Assessment ................................................................................................ 17
`1.4. Patient Experience Data ................................................................................................. 20
`2. Therapeutic Context .............................................................................................................. 21
`2.1. Analysis of Condition ...................................................................................................... 21
`2.2. Analysis of Current Treatment Options ......................................................................... 22
`3. Regulatory Background ......................................................................................................... 24
`3.1. U.S. Regulatory Actions and Marketing History ............................................................. 24
`3.2.
`Summary of Presubmission/Submission Regulatory Activity ........................................ 24
`4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on
`Efficacy and Safety ................................................................................................................. 24
`4.1. Office of Scientific Investigations (OSI) .......................................................................... 24
`4.2. Product Quality .............................................................................................................. 25
`4.3. Devices and Companion Diagnostic Issues .................................................................... 26
`5. Nonclinical Pharmacology/Toxicology................................................................................... 27
`5.1. Executive Summary ........................................................................................................ 27
`5.2. Toxicology ....................................................................................................................... 27
`6. Clinical Pharmacology ............................................................................................................ 29
`6.1. Executive Summary ........................................................................................................ 29
`6.2.
`Summary of Clinical Pharmacology Assessment ............................................................ 30
`6.3. Clinical Pharmacology Background ................................................................................ 31
`6.3.1. Background ............................................................................................................. 31
`6.3.2. What is the relevant regulatory background pertinent to this application? ......... 31
`6.3.3. What are the clinical pharmacology studies submitted to support this NDA? ...... 32
`6.4. Comprehensive Clinical Pharmacology Review ............................................................. 32
`6.4.1. What are the proposed mechanism of action and therapeutic indications? ......... 32
`6.4.2. What are the proposed dosages and routes of administration? ........................... 33
`6.4.3. What are the design features of the clinical pharmacology and clinical studies
`used to support dosing or claims? .................................................................................... 33
`
`
`Version date: September 12, 2018
`
`
`
`2
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`6.4.4. What are the characteristics of the dose/exposure‐response relationship for the
`effectiveness? ................................................................................................................... 35
`6.4.5. What are the characteristics of the dose/exposure‐response relationships for
`safety? ............................................................................................................................... 37
`6.4.6. What are the PK parameters of aclidinium and formoterol in healthy subjects? .. 38
`6.4.7. What are the PK parameters of aclidinium and formoterol in patients with COPD
`following multiple administration? .................................................................................. 40
`6.4.8. How is the proposed to‐be‐marketed formulation linked to the clinical
`formulation? ..................................................................................................................... 41
`6.5. Bioanalytical section ....................................................................................................... 41
`6.5.1. What are the analytical methods used to measure aclidinium in plasma? ........... 41
`6.5.2. What are the analytical methods used to measure formoterol in plasma? .......... 42
`6.5.3. What are the results for the re‐analysis of the incurred samples? ........................ 43
`7. Sources of Clinical Data and Review Strategy ....................................................................... 44
`7.1. Table of Clinical Studies .................................................................................................. 44
`7.2. Review Strategy .............................................................................................................. 45
`8. Statistical and Clinical and Evaluation ................................................................................... 45
`8.1. Review of Relevant Individual Trials Used to Support Efficacy ...................................... 45
`8.1.1. Trials 30, 31, 01, and 02 .......................................................................................... 45
`8.1.2. Study Results ........................................................................................................... 71
`8.1.3. Assessment of Efficacy Across Trials ....................................................................... 91
`8.1.4. Integrated Assessment of Effectiveness ................................................................. 99
`8.2. Review of Safety ........................................................................................................... 100
`8.2.1. Safety Review Approach ....................................................................................... 100
`8.2.2. Review of the Safety Database ............................................................................. 100
`8.2.3. Adequacy of Applicant’s Clinical Safety Assessments .......................................... 102
`8.2.4. Safety Results ........................................................................................................ 103
`8.2.5. Analysis of Submission‐Specific Safety Issues ....................................................... 118
`8.2.6. Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability ...... 125
`8.2.7. Safety Analyses by Demographic Subgroups ........................................................ 125
`8.2.8. Specific Safety Studies/Clinical Trials .................................................................... 125
`8.2.9. Additional Safety Explorations .............................................................................. 125
`8.2.10.
`Safety in the Postmarket Setting ................................................................... 126
`8.2.11.
`Integrated Assessment of Safety ................................................................... 126
`Statistical Issues ........................................................................................................... 126
`8.3.
`8.4. Conclusions and Recommendations ............................................................................ 130
`9. Advisory Committee Meeting and Other External Consultations ....................................... 131
`10. Pediatrics ............................................................................................................................. 131
`11. Labeling Recommendations ................................................................................................ 132
`11.1.
`Prescription Drug Labeling ....................................................................................... 132
`
`3
`
`
`Version date: September 12, 2018
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`12. Risk Evaluation and Mitigation Strategies (REMS) .............................................................. 133
`13. Postmarketing Requirements and Commitment ................................................................ 133
`14. Division Director (Clinical) Comments ................................................................................. 134
`15. Appendices .......................................................................................................................... 136
`15.1.
`References ................................................................................................................ 136
`15.2.
`Financial Disclosure .................................................................................................. 136
`
`
`
`
`
`
`
`Version date: September 12, 2018
`
`
`
`4
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Table of Tables
`
`Table 1: Current COPD treatment options ................................................................................... 23
`Table 2. Arithmetic mean PK parameters for aclidinium and formoterol after single dose
`administration in healthy subjects (Study M/40464/02) ............................................................. 30
`Table 3: Listing of clinical pharmacology studies in support of this NDA ..................................... 32
`Table 4. Validation summary of bioanalytical method for aclidinium ......................................... 41
`Table 5. Validation summary of bioanalytical method for formoterol ........................................ 42
`Table 6. Reviewed trials ................................................................................................................ 44
`Table 7. Trial 30 Assessment Schedule ......................................................................................... 47
`Table 8: Sequence of null hypotheses for multiplicity adjustment .............................................. 54
`Table 9: Assessment Schedule, Trial 31 ........................................................................................ 57
`Table 10: Concomitant/Restricted Medications, Trial 31 ............................................................. 58
`Table 11: Assessment Schedule, Trial 01 ...................................................................................... 62
`Table 12: Concomitant Medications, Trial 01 ............................................................................... 65
`Table 13: Restricted Medications, Trial 01 ................................................................................... 66
`Table 14: Objectives and Endpoints, Trial 01................................................................................ 67
`Table 15: Sequence of testing for multiplicity adjustment, Trial 01 ............................................ 69
`Table 16: Pooled Patient Disposition, Trials 30 and 31 ................................................................ 72
`Table 17: Patient Disposition, Trial 01 .......................................................................................... 73
`Table 18: Pooled Patient Demographic and Baseline Characteristics, Trials 30 and 31 .............. 74
`Table 19: Patient Demographic and baseline Characteristics, Trial 01 ........................................ 75
`Table 20: Change from baseline in 1‐hour morning post‐dose FEV1 (L) at Week 24, AB/FF 400/12
`µg versus AB 400 µg, ITT population ............................................................................................ 77
`Table 21: Change from baseline in pre‐dose FEV1 at Week 24, AB/FF 400/12 µg versus FF 12 µg,
`ITT population ............................................................................................................................... 78
`Table 22: Change from baseline in SGRQ total score (Units) at Week 24, ITT population (Trials 30
`and 31) .......................................................................................................................................... 80
`Table 23: Number (%) of patients achieving a clinically meaningful improvement (a decrease of
`at least 4‐units) from baseline in SGRQ total score over at Week 24, ITT population ................. 80
`Table 24: Change from baseline normalized AUC 0‐3h FEV1 at Week 24, ITT population, Trial 01 81
`Table 25: Change from baseline normalized AUC 0‐3h FEV1 at Week 24, ITT population ............. 82
`Table 26: Change from baseline in 1‐hour morning post‐dose FEV1 at Week 24, AB/FF 400/6 µg
`and AB/FF 400/12 µg versus placebo in Trials 30 and 31 (ITT population) .................................. 86
`Table 27: Change from baseline in morning pre‐dose (trough) FEV1 at Week 24, AB/FF 400/6 µg
`and AB/FF 400/12 µg versus placebo, Trials 30 and 31 (ITT population) ..................................... 87
`Table 28: Rate of moderate‐to‐severe exacerbation per patient/year, pooled Trials 30 and 31
`(post‐hoc analysis) ........................................................................................................................ 93
`Table 29: Treatment Exposure, Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31) 100
`Table 30: Treatment Exposure, 28‐Week Placebo‐Controlled Extension Trial (Trial 36) ........... 101
`Table 31: Treatment Exposure, 24‐Week Active‐Controlled Trial (Trial 01) .............................. 102
`Table 32: Treatment‐Emergent Deaths, Pooled 24‐Week Placebo‐Controlled Trials ................ 103
`Table 33: Treatment‐Emergent Deaths, 28‐Week Placebo‐Controlled Extension (Trial 36). .... 104
`
`
`5
`Version date: September 12, 2018
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Table 34: Treatment‐Emergent Deaths, 24‐Week Active‐Controlled Trial (Trial 01) ................. 105
`Table 35: Treatment‐Emergent Non‐Fatal SAEs That Occurred in Approximately 1% of Total
`Patients (by SOC), Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31) ..................... 106
`Table 36: Treatment‐Emergent Non‐Fatal SAEs That Occurred in ≥ 2 Patients in Any Treatment
`Group (by PT), 28‐Week Placebo‐Controlled Extension Trial (Trial 36) ..................................... 108
`Table 37: Discontinuations Due to Adverse Events That Occurred in ≥ 2 Patients in Any
`Treatment Group (by PT), Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31) ......... 109
`Table 38: Discontinuations Due to Adverse Events That Occurred in ≥ 2 Patients in Any
`Treatment Group (by PT), 28‐Week Placebo‐Controlled Extension Trial (Trial 36) ................... 110
`Table 39: Severe TEAEs That Occurred in ≥2 Patients in Any Treatment Group (by PT) Pooled 24‐
`Week Placebo‐Controlled Trials (Trials 30 and 31) ..................................................................... 111
`Table 40: 2 Severe TEAEs That Occurred in ≥2 patients in Any Treatment Group (by PT) 8‐Week
`Placebo‐Controlled Extension Trial (Trial 36) ............................................................................. 112
`Table 41: TEAE that Occurred in ≥ 2% of Patients in Any Treatment Group (by PT) Pooled 24‐
`Week Placebo‐Controlled Trials (Trial 30 and 31). ..................................................................... 113
`Table 42: TEAE That Occurred in ≥ 2% of Patients in any Treatment Group (by PT) 28‐Week
`Placebo‐Controlled Extension Trial (Trial 36) ............................................................................. 114
`Table 43: Number of Patients With PCS Changes in 12‐lead ECG Values at EOS Pooled 24‐Week
`Placebo‐Controlled Trials ............................................................................................................ 117
`Table 44: Treatment‐Emergent and Serious Treatment‐Emergent Adverse Events of LRTI,
`Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31). .................................................. 118
`Table 45: MACE Analysis, Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31) .......... 119
`Table 46: Cardiac Events of Special Interest by Specific SMQ Category, Pooled 24‐Week Placebo‐
`Controlled Trials (Trials 30 and 31) ............................................................................................. 120
`Table 47: Cerebrovascular Adverse Events by Specific SMQ category, Pooled 24‐Week Placebo‐
`Controlled Trials .......................................................................................................................... 121
`Table 48: Anticholinergic Events, Pooled 24‐Week Placebo‐Controlled Trials (Trials 30 and 31)
`..................................................................................................................................................... 121
`Table 49: β2‐Agonist Events, Pooled 24‐Week Placebo‐Controlled Trials. ................................ 123
`Table 50: Pattern‐Mixture model for the change from baseline in 1‐hour morning postdose FEV1
`(L) at Week 24, ITT population (Trial 31) .................................................................................... 128
`Table 51: Pattern‐Mixture model for the change from baseline in trough FEV1 (L) at Week 24,
`ITT population (Trial 31) .............................................................................................................. 129
`Table 52: Pattern‐Mixture model for the change from baseline in 1‐hour morning postdose FEV1
`(L) at Week 24, ITT population (Trial 30) .................................................................................... 129
`Table 53: Pattern‐Mixture model for the change from baseline in trough FEV1 (L) at Week 24,
`ITT population (Trial 30) .............................................................................................................. 130
`
`
`
`
`
`
`Version date: September 12, 2018
`
`
`
`6
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Table of Figures
`
`Figure 1: Change from baseline in (A) FEV1 (L) at each specific timepoint on Day 14; (B)
`normalized FEV1 AUC0‐6h (L) at Day 14 (Study LAC‐MD‐21) ......................................................... 36
`Figure 2: LS mean change from baseline FEV1(L) at each specific timepoint on Day 7 (Study
`D6571C00002) .............................................................................................................................. 36
`Figure 3: Change from baseline in FEV1 by time point at Day 14 (Study LAC‐MD‐27) ................ 37
`Figure 4: Plasma concentration‐time profile for aclidinium in healthy subjects; (inset) plasma
`concentration‐time profile for 2 hr to demonstrate variability around Cmax (Study M/40464/02)
`....................................................................................................................................................... 39
`Figure 5: Plasma concentration‐time profile for formoterol in healthy subjects (Study
`M/40464/02) ................................................................................................................................. 40
`Figure 6: Mean (+SD) steady state plasma concentration‐time profile of aclidinium and
`formoterol following AB/FF 400 µg/12 µg BID administration in COPD patients (Study LAC‐PK‐
`01) ................................................................................................................................................. 41
`Figure 7: Change from baseline in serial FEV1 over 12‐hours post‐dose on Day 1 (ITT population),
`Trial 30 .......................................................................................................................................... 83
`Figure 8: Change from baseline in serial FEV1 over 12‐hours post‐dose at Week 24 (ITT
`population), Trial 30 ...................................................................................................................... 83
`Figure 9: Change from baseline in serial FEV1 over 12‐hours post‐dose on Day 1 (ITT population),
`Trial 31 .......................................................................................................................................... 84
`Figure 10: Change from baseline in serial FEV1 over 12‐hours post‐dose at Week 24 (ITT
`population), Trial 31 ...................................................................................................................... 84
`Figure 11: Change from baseline in serial FEV1 over 12‐hours post‐dose on Day 1 (ITT
`population), Trial 01 ...................................................................................................................... 85
`Figure 12: Change from baseline in serial FEV1 over 12‐hours post‐dose at Week 24 (ITT
`population), Trial 01 ...................................................................................................................... 85
`Figure 13: Change from baseline at 1‐hour post‐dose in FEV1 (L) over 24 weeks, Trial 30, ITT
`population ..................................................................................................................................... 88
`Figure 14: Change from baseline in morning pre‐dose (trough) FEV1 (L) over 24 weeks, Trial 30,
`ITT population ............................................................................................................................... 88
`Figure 15. Change from baseline at 1‐hour post‐dose in FEV1 (L) over 24 weeks, Trial 31, ITT
`population ..................................................................................................................................... 89
`Figure 16: Change from baseline in morning pre‐dose (trough) FEV1 (L) over 24 weeks, Trial 31,
`ITT population ............................................................................................................................... 89
`Figure 17: Change from baseline at 1‐hour post‐dose in FEV1 (L) over 24 weeks, Trial 01, ITT
`population ..................................................................................................................................... 90
`Figure 18: Change from baseline in morning pre‐dose (trough) FEV1 (L) over 24 weeks, Trial 01,
`ITT population ............................................................................................................................... 90
`Figure 19: LS mean treatment differences and 95% CI between AB/FF 400/12 µg and AB 400 µg
`in the change from baseline at Week 24 in FEV1 at 1 hour post‐dose, pooled ITT populations of
`Trials 30, 31, and 01 ...................................................................................................................... 94
`
`
`Version date: September 12, 2018
`
`
`
`7
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Figure 20: LS mean treatment differences and 95% CI between AB/FF 400/12 µg and FF 12 µg
`in the change from baseline to Week 24 in pre‐dose trough FEV1 in the pooled ITT populations
`of Trials 30, 31, and 01 .................................................................................................................. 95
`Figure 21: Comparison of subgroup analysis using sample estimates and Bayesian shrinkage
`estimates: treatment differences and 95% CI between AB/FF 400/12 µg and FF 12 µg in the
`change from baseline to pre‐dose trough FEV1 at Week 24 i in the pooled ITT populations of
`Trials 30, 31, and 01 ...................................................................................................................... 97
`Figure 22: Comparison of subgroup analysis using sample estimates and Bayesian shrinkage
`estimates: treatment differences and 95% CI between AB/FF 400/12 µg and AB 400 µg in the
`change from baseline to Week 24 in FEV1 at 1 hour post‐dose in the pooled ITT populations of
`Trials 30, 31, and 01 ...................................................................................................................... 98
`
`
`
`
`
`
`
`Version date: September 12, 2018
`
`
`
`8
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Reviewers of Multi‐Disciplinary Review and Evaluation
`
`Regulatory Project Manager
`Nonclinical Reviewer
`Nonclinical Team Leader
`Office of Clinical Pharmacology Reviewer(s)
`Office of Clinical Pharmacology Team Leader(s)
`Clinical Reviewer
`Clinical Team Leader
`Statistical Reviewer
`Statistical Team Leader
`Cross‐Disciplinary Team Leader
`Division Director, DPARP (or designated signatory
`authority)
`
`Ngoc‐Linh Do, PharmD
`Anup Srivastava, PhD
`Carol Galvis, PhD
`Mohammad Absar, PhD
`Bavna Saluja, PhD
`Liangfeng Han
`Robert Lim, MD
`Mingyu Xi, PhD
`Yongman Kim, PhD
`Robert Lim, MD
`Banu Karimi‐Shah, MD
`
`
`Additional Reviewers of Application
`OPQ
`Craig Bertha, PhD
`Microbiology
`
`OPDP
`Taylor Burnett, PharmD
`OSI
`
`OSE/DEPI
`
`OSE/DMEPA
`Lissa Owen, PharmD; Matt Barlow, RN, BSN
`OSE/DRISK
`
`Other/ Patient Labeling
`Kelly Jackson, PharmD
`OPQ=Office of Pharmaceutical Quality
`OPDP=Office of Prescription Drug Promotion
`OSI=Office of Scientific Investigations
`OSE= Office of Surveillance and Epidemiology
`DEPI= Division of Epidemiology
`DMEPA=Division of Medication Error Prevention and Analysis
`DRISK=Division of Risk Management
`
`
`
`
`
`Version date: September 12, 2018
`
`
`
`9
`
`
`
`Reference ID: 4410728Reference ID: 4411515
`
`
`
`NDA/BLA M ult i-disciplinary Review and Evaluation {NOA 210595}
`{Duaklir Pressair, Aclidi nium Bromide/Formoterol Fumarate inhalation powder}
`Signatures
`
`DISCIPLINE
`
`REVIEWER
`
`OFFICE/DIVISION
`
`SECTIONS
`AUTHORED/
`APPROVED
`
`Nonclinical
`Reviewer
`
`Nonclinical
`Team Leader
`
`Clinical
`Pharmacology
`Reviewer
`
`An up K.
`Srivastava
`
`Signature:
`
`Carol M .
`Galvis, PhD
`
`Signature:
`
`Mohammad
`Absar, PhD
`
`Signature:
`
`OND/ODEll/DPARP
`
`Sections:S
`
`OND/ODEll/DPARP
`
`Sections: 5
`
`OTS/OCP/DCP2
`
`Sections: 6
`
`AUTHORED/
`APPROVED
`
`Select one:
`..L Authored
`_
`Approved
`
`Select one:
`
`Authored
`-
`..L Approved
`
`Select one:
`..L Authored
`_
`Approved
`
`Version date: September 12, 2018
`
`10
`
`Reference ID: 441 IHllS
`
`
`
`NDA/ BLA M ult i-disciplinary Review and Eva luation {NOA 210595}
`{Duaklir Pressair, Acl idinium Bromide/ Formoterol Fumarate inhalation powder}
`
`DISCIPLINE
`
`REVIEWER
`
`OFFICE/DIVISION
`
`Shaw ana
`Saluja
`
`Office of Clinical
`Pharmacology/DCP2
`
`Clinical
`Pharmacology
`Team Leader
`
`Clinical Review er
`
`SECTIONS
`AUTHORED/
`APPROVED
`
`Section: 6
`
`AUTHORED/
`APPROVED
`
`Select one:
`
`Aut hored
`-
`_x_ Approved
`
`Select one:
`_x_ Authored
`
`_
`
`Approved
`
`Signature:
`
`Robert Lim
`signing for
`Liangfeng Han
`
`Signature:
`
`ON D/ ODEll/DPARP
`
`Sect ions: 1-4, 7-13
`
`Version date: September 12, 2018
`
`11
`
`Reference ID: 441 IHllS
`
`
`
`NDA/ BLA M ult i-disciplinary Review and Evaluation {NOA 210595}
`{Duaklir Pressair, Aclidi nium Bromide/ Formoterol Fumarate inhalation powder}
`
`DISCIPLINE
`
`REVIEWER
`
`OFFICE/DIVISION
`
`SECTIONS
`AUTHORED/
`APPROVED
`
`Clinical Team
`Leader
`
`Division Director
`(or designat ed
`signatory
`authority)
`
`Robert Lim,
`M D
`
`Signature:
`
`Banu Karimi-
`Shah, M D
`
`Signature:
`
`OND/ ODEll/ DPARP
`
`Sections: 1-4, 7-13, 15
`
`OND/ ODEll/ DPARP
`
`Sections:
`
`M ingyu Xi
`
`Office of Biostatist ics/ DB2
`
`Sect ions: 8
`
`Statistical
`Reviewer
`
`Signature:
`
`Yongman Kim Office of Biostatist ics/ DB2
`
`Sections: 8
`
`Statistical Team
`Leader
`
`Signature:
`
`Lei Nie
`
`Office of Biostatist ics/ DB2
`
`Sections: 8
`
`Acting Deput y
`Division Director
`(OB)
`
`Signature:
`
`AUTHORED/
`APPROVED
`
`Select one:
`.lL Authored
`_x_ Approved
`
`Select one:
`Authored
`
`-
`_X_ Approved
`
`Select one:
`.lL Authored
`_
`Approved
`
`Select one:
`Authored
`
`-
`_X_ Approved
`
`Select one:
`Authored
`
`-
`_X_ Approved
`
`Version date: September 12, 2018
`
`12
`
`Reference ID: 441 IHllS
`
`
`
`NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595}
`{Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder}
`Glossary
`
`
`AC
`ADME
`AE
`
`AR
`
`BLA
`
`BPCA
`
`BRF
`
`CBER
`
`CDER
`
`CDRH
`
`CDTL
`
`CFR
`
`CMC
`
`COSTART
`CRF
`
`CRO
`
`CRT
`
`CSR
`
`CSS
`
`DHOT
`DMC
`
`ECG
`
`eCTD
`
`ETASU
`FDA
`
`FDAAA
`FDASIA
`GCP
`
`GRMP
`IC
`
`ICH
`
`IND
`
`ISE
`
`ISS
`
`ITT
`
`MedDRA
`mITT
`
`NCI‐CTCAE
`NDA
`
`NME
`
`OCS
`
`
`Version date: September 12, 2018
`
`advisory committee
`absorption, distribution, metabolism, excretion
`adverse event
`adverse reaction
`biologics license application
`Best Pharmaceuticals for Children Act
`Benefit Risk Framework
`Center for Biologics Evaluation and Research
`Center for Drug Evaluation and Research
`Center for Devices and Radiological Health
`Cross‐Discipline Team Leader
`Code of Federal Regulations
`chemistry, manufacturing, and controls
`Coding Symbols for Thesaurus of